ИСТИНА |
Войти в систему Регистрация |
|
ФНКЦ РР |
||
Determination of minimal residual disease (MRD) has become an integral part of the comprehensive definition of the antitumor therapy effectiveness in case of acute lymphoblastic leukemia (ALL). There is no doubt that it is necessary to estimate MRD during the period of remission induction and before allogeneic hematopoietic stem cell transplantation. However, the prognostic value of MRD at the post-induction phase of treatment is still being actively studied.